Erratum to: A rapid immunization strategy with a live-attenuated tetravalent dengue vaccine elicits protective neutralizing antibody responses in non-human primates [Front Immunol, 5, 263, (2014)] doi: 10.3389/fimmu.2014.00263;A rapid immunization strategy with a live-attenuated tetravalent dengue vaccine elicits protective neutralizing antibody responses in non-human primates

Frontiers in Immunology

Volumn 5, Issue JUN, 2014, Pages

  Ambuel, Yuping ^a   Young, Ginger ^a   Brewoo, Joseph N ^a   Paykel, Joanna ^a   Weisgrau, Kim L ^b   Rakasz, Eva G ^b   Haller, Aurelia A ^c   Royals, Michael ^d   Huang, Claire Y H ^e   Capuano, Saverio ^b   Stinchcomb, Dan T ^c   Partidos, Charalambos D ^a   Osorio, Jorge E ^a  

^a Takeda Vaccines Inc   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c Takeda Vaccines Inc   (United States)

^d PharmaJet Inc   (United States)

^e NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

Dengue; Needle free delivery; Neutralizing antibodies; Non human primates; T cell responses; Vaccine

Indexed keywords

DENGUE VACCINE; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 1; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DENGUE; FLOW CYTOMETRY; MACACA; MALE; NONHUMAN; PRIMATE DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; VACCINATION;

EID: 84905667227     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00436     Document Type: Erratum

References (27)

1. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, et al. Dengue: a continuing global threat. Nat Rev Microbiol (2010) 8:S7-16. doi: 10.1038/nrmicro2460
2. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature (2013) 496:504-7. doi:10.1038/nature12060
3. Gubler DJ. Dengue, urbanization and globalization: the unholy trinity of the 21(st) century. Trop Med Health (2011) 39:3-11. doi:10.2149/tmh.2011-S05
4. Martina BE, Koraka P, Osterhaus AD. Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev (2009) 22:564-81. doi:10.1128/CMR.00035-09
5. Whitehorn J, Simmons CP. The pathogenesis of dengue. Vaccine (2011) 29:7221-8. doi:10.1016/j.vaccine.2011.07.022
6. Halstead SB, Mahalingam S, Marovich MA, Ubol S, Mosser DM. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis (2010) 10:712-22. doi:10.1016/S1473-3099(10)70166-3
7. Rothman AL. Dengue: defining protective versus pathologic immunity. J Clin Invest (2004) 113:946-51. doi:10.1172/JCI21512
8. Rothman AL. T lymphocyte responses to heterologous secondary dengue virus infections. Ann N Y Acad Sci (2009) 1171:E36-41. doi:10.1111/j.1749-6632.2009.05055.x
9. Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol (2007) 5:518-28. doi:10.1038/nrmicro1690
10. Huang CY-H, Butrapet S, Tsuchiya KR, Bhamarapravati N, Gubler DJ, Kinney RM. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J Virol (2003) 77:11436-47. doi:10.1128/JVI.77.21.11436-11447.2003
11. Huang CY-H, Butrapet S, Pierro DJ, Chang GJJ, Hunt AR, Bhamarapravati N, et al. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol (2000) 74:3020-8. doi:10.1128/JVI.74.7.3020-3028.2000
12. Kinney RM, Butrapet S, Chang GJ, Tsuchiya KR, Roehrig JT, Bhamarapravati N, et al. Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology (1997) 230:300-8. doi:10.1006/viro.1997.8500
13. Butrapet S, Huang CY, Pierro DJ, Bhamarapravati N, Gubler DJ, Kinney RM. Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53) are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3. J Virol (2000) 74:3011-9. doi:10.1128/JVI.74.7.3011-3019.2000
14. Vaughn DW, Hoke CH Jr., Yoksan S, LaChance R, Innis BL, Rice RM, et al. Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. Vaccine (1996) 14:329-36. doi:10.1016/0264-410X(95)00167-Y
15. Bhamarapravati N, Yoksan S, Chayaniyayothin T, Angsubphakorn S, Bunyaratvej A. Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers. Bull World Health Organ (1987) 65:189-95.
16. Brewoo JN, Kinney RM, Powell TD, Arguello JJ, Silengo SJ, Partidos CD, et al. Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice. Vaccine (2012) 30:1513-20. doi:10.1016/j.vaccine.2011.11.072
17. Osorio JE, Brewoo JN, Silengo SJ, Arguello J, Moldovan IR, Tary-Lehmann M, et al. Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques. Am J Trop Med Hyg (2011) 84:978-87. doi:10.4269/ajtmh.2011.10-0592
18. Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine (2008) 26:3197-208. doi:10.1016/j.vaccine.2008.03.095
19. Huang CY, Kinney RM, Livengood JA, Bolling B, Arguello JJ, Luy BE, et al. Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax). PLoS Negl Trop Dis (2013) 7:e2243. doi:10.1371/journal.pntd.0002243
20. Butrapet S, Kinney RM, Huang CY. Determining genetic stability of chimeric dengue vaccine candidates based on dengue 2 PDK-53 virus by sequencing and quantitative TaqMAMA. J Virol Methods (2006) 131:1-9. doi:10.1016/j.jviromet.2005.06.019
21. Fried JR, Gibbons RV, Kalayanarooj S, Thomas SJ, Srikiatkhachorn A, Yoon IK, et al. Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006. PLoS Negl Trop Dis (2010) 4:e617. doi:10.1371/journal.pntd.0000617
22. Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A (2013) 110:E2046-53. doi:10.1073/pnas.1305227110
23. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet (2012) 380:1559-67. doi:10.1016/S0140-6736(12)61428-7
24. Halstead SB. Identifying protective dengue vaccines: guide to measuring an empirical process. Vaccine (2013) 31:4501-7. doi:10.1016/j.vaccine.2013.06.079
25. Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, Sukupolvi-Petty S, et al. Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol (2006) 80:12149-59. doi:10.1128/JVI.01732-06
26. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, et al. Dengue in the early febrile phase: viremia and antibody responses. J Infect Dis (1997) 176:322-30. doi:10.1086/514048
27. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis (2000) 181:2-9. doi:10.1086/315215